{
    "clinical_study": {
        "@rank": "95981", 
        "acronym": "MGD006-01", 
        "arm_group": {
            "arm_group_label": "MGD006", 
            "arm_group_type": "Experimental", 
            "description": "MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) bi-specific antibody"
        }, 
        "brief_summary": {
            "textblock": "The primary goal of this Phase 1, dose-escalation study, is to determine the maximum\n      tolerated dose level of MGD006 in patients with AML whose disease is not expected to benefit\n      from cytotoxic chemotherapy. Studies will also be done to see how the drug acts in the body\n      (pharmacokinetics, pharmacodynamics)  and to evaluate potential anti-tumor activity of\n      MGD006."
        }, 
        "brief_title": "Safety Study of MGD006 in Relapsed/Refractory AML", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "AML", 
        "detailed_description": {
            "textblock": "Open-label, multi-dose, single-arm, multi-center, Phase 1, dose-escalation study to define a\n      MTDS, describe preliminarily safety, and to assess PK, immunogenicity, immunomodulatory\n      activity, and potential anti-tumor activity of MGD006 in patients with AML whose disease is\n      not expected to benefit from cytotoxic chemotherapy.\n\n      This study is designed in three segments: the Single Patient Dose Escalation Segment,\n      followed by the Multi-Patient Dose Escalation Segment and the MTDS Expansion Cohort Segment.\n      Transition to the Multi-Patient Dose Escalation Segment of the study will be based on review\n      of the aggregate safety data on all patients participating in Cohort 0.\n\n      The Multi-Patient Dose Escalation Segment will employ a classical 3+3 scheme to examine a\n      series of increasing one-step dose escalations in sequential cohorts of patients.\n\n      Once the MTDS is established, the cohort of patients treated at that dose/schedule will be\n      expanded with the addition of 12 patients to increase the safety experience and more fully\n      evaluate the PK and pharmacodynamics of MGD006.\n\n      In all segments of the study, patients who benefit from MGD006 treatment, and continue to\n      meet eligibility, may continue treatment in Cycles 2 and beyond."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  confirmed diagnosis of primary or secondary AML [any subtype except acute\n             promyelocytic leukemia (APL)] according to World Health Organization (WHO)\n             classification.\n\n          -  Patients must be unlikely to benefit from cytotoxic chemotherapy defined by any one\n             of the following criteria:\n\n               -  newly diagnosed leukemia refractory to \u2265 2 induction attempts,\n\n               -  leukemia in 1st relapse with initial CR duration < 6 months,\n\n               -  leukemia in 1st relapse following \u2265 1 unsuccessful salvage attempts, or\n\n               -  leukemia in 2nd or higher relapse.\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status </= 1\n\n          -  Life expectancy of at least 4 weeks\n\n          -  Peripheral blast count </= 20,000/mm3 at the time of initiation of infusion on Cycle\n             1 Day 1\n\n          -  Acceptable laboratory parameters and adequate organ reserve\n\n          -  Adult (\u2265 18 years old)\n\n        Exclusion Criteria:\n\n          -  Prior history of allogeneic stem cell transplantation\n\n          -  Prior treatment with an anti-CD123-directed agent\n\n          -  Need for concurrent other cytoreductive chemotherapy\n\n          -  Any prior history of or suspected current autoimmune disorders (with the exception of\n             vitiligo, resolved childhood atopic dermatitis, prior Grave's disease now euthyroid\n             clinically and by laboratory testing)\n\n          -  Second primary malignancy that has not been in remission for greater than 3 years.\n             Treated non-melanoma skin cancer, cervical carcinoma in situ on biopsy, or squamous\n             intraepithelial lesion on PAP smear, or resected melanoma in situ are exceptions and\n             do not require a 3-year remission\n\n          -  Previous treatment with radiotherapy or immunotherapeutic agents in the 4 weeks prior\n             to study drug administration (Cycle 1 Day 1)\n\n          -  Previous treatment with any other investigational agent in the 4 weeks prior to study\n             drug administration (Cycle 1 Day 1)\n\n          -  Requirement, at the time of study entry, for concurrent steroids > 10 mg/day of oral\n             prednisone or the equivalent, except steroid inhaler, nasal spray or ophthalmic\n             solution\n\n          -  Use of immunosuppressant medications in the 4 weeks prior to study drug\n             administration (Cycle 1 Day 1)\n\n          -  Use of granulocyte colony stimulating or granulocyte-macrophage colony stimulating\n             factor in the 4 weeks prior to study drug administration (Cycle 1 Day 1)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "58", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02152956", 
            "org_study_id": "CP-MGD006-01"
        }, 
        "intervention": {
            "arm_group_label": "MGD006", 
            "description": "MGD006 is a CD123 x CD3 bi-specific antibody-based molecular construct referred to as a dual affinity re-targeting (DART) molecule. MGD006 will be administered as a single agent.", 
            "intervention_name": "MGD006", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Antibodies, Bispecific"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "AML", 
            "leukemia", 
            "myelogenous"
        ], 
        "lastchanged_date": "May 28, 2014", 
        "location": {
            "contact": {
                "email": "kmaus@DOM.wustl.edu", 
                "last_name": "Kathryn Maus", 
                "phone": "314-747-1849"
            }, 
            "facility": {
                "address": {
                    "city": "St. Louis", 
                    "country": "United States", 
                    "state": "Missouri", 
                    "zip": "63110"
                }, 
                "name": "Washington University School of Medicine"
            }, 
            "investigator": {
                "last_name": "Geoff Uy, MD, PhD", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory Acute Myeloid Leukemia", 
        "overall_contact": {
            "email": "richardsl@macrogenics.com", 
            "last_name": "Lori Richards", 
            "phone": "650-624-2609"
        }, 
        "overall_official": [
            {
                "affiliation": "Washington University School of Medicine", 
                "last_name": "John DiPersio, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "MacroGenics", 
                "last_name": "Stanford Stewart, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Safety is based on evaluation of adverse events (AEs) and serious adverse events (SAEs) from the time of study drug administration through the End of Study Visit.  Safety review for the purposes of dose escalation and/or study segment transition will be based on AEs collected during the first cycle of treatment.\nMaximum Tolerated Dose/Schedule: the MTDS will be defined as the highest dose/schedule administered during any Cohort in the study at which the incidence of DLT is < 33% during the first cycle of MGD006 treatment.", 
            "measure": "Characterize dose limiting toxicity and to establish a Maximum Tolerated Dose and Schedule (MTDS).", 
            "safety_issue": "Yes", 
            "time_frame": "Cycle 1 of a 28 day cycle."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02152956"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Evaluation of DLTs, treatment emergent adverse events (TEAEs), and the aggregate safety data", 
                "measure": "Describe the safety profile of MGD006", 
                "safety_issue": "Yes", 
                "time_frame": "Cycle 1 through end of treatment"
            }, 
            {
                "description": "Serum concentrations of MGD006 will be monitored. Population PK modeling will be performed and an appropriate model will be selected to describe the data.", 
                "measure": "Characterize the PK and immunogenicity of MGD006", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1 through end of treatment (28 day cycles)"
            }, 
            {
                "description": "Obtain bone marrow aspirate and/or biopsy specimen for local histopathological and immunohistochemical analysis", 
                "measure": "Describe any evidence of anti-leukemic activity", 
                "safety_issue": "No", 
                "time_frame": "Every 28 days"
            }
        ], 
        "source": "MacroGenics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "MacroGenics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}